Predict your next investment

Private Equity
necapitalpartners.com

See what CB Insights has to offer

Investments

58

Portfolio Exits

17

About New England Partners

NECP is a private equity investment firm focused on acquiring lower middle-market operating companies. NECP is a successor to and affiliate of New England Capital Management, which has been successfully acquiring and growing small businesses since 1991. NECP is interested in acquiring companies with annual sales in the $3 to $30 million range, at transaction prices upward to $30 million. Manufacturing, Distribution and Service industries located in the Northeast are preferred, but other locations and industries will be considered.We enjoy assisting experienced and entrepreneurial owners in realizing their transitional goals. Depending on the desires of an owner, we will either provide partial liquidity and supplement current management or purchase companies outright and bring new management to the company.The principals of NECP are Kevin McCafferty and Bob Winneg. Mr. McCafferty has been in the private equity business since 1977. He is co-founder and Chairman of New England Capital Management. Previously he was a Partner in Madison Dearborn Partners. Mr. Winneg has been a private equity investor since 1990. Prior to NECP he was a partner at Heritage Partners, investing principally in family owned businesses. He has successfully completed numerous transactions, financings, and strategic initiatives.If you would like further information about New England Capital Partners please do not hesitate to call. We would love to hear from you.

New England Partners Headquarter Location

One Gateway Center Suite 405

Newton, Massachusetts, 02458,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest New England Partners News

Health New England Partners with Healthmap Solutions to Provide Kidney Health Management Program to Members

Nov 5, 2020

| Source: Healthmap Solutions; Health New England TAMPA, Fla., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Health New England announced today a new partnership with Healthmap Solutions (Healthmap), an industry-leading Kidney Health Management (KHM) company. Effective December 1, 2020, the KHM program will be available to Health New England’s Medicare Advantage, Commercial and Medicaid members living with chronic kidney disease (CKD) and end-stage renal disease (ESRD). “Chronic kidney disease is a progressive and usually silent condition that can end in tremendous debilitation, including a need for dialysis, which our members, particularly those with diabetes and/or hypertension, may be at risk for,” said Ira M. Klein, MD, MBA, FACP, Vice President and Chief Medical Officer at Health New England. “In my past work with the National Kidney Foundation in the creation of new quality metrics, I’ve seen how we need to raise awareness and management of this devastating disease, and I am excited to have Healthmap as our partner in Health New England’s advocacy to help our members achieve their best health goals.” People living with CKD or ESRD often have co-morbid conditions, such as diabetes and hypertension, which require multidisciplinary care, including extensive treatment and medication regimens to remain healthy for as long as possible. According to the Centers for Disease Control and Prevention, 37 million people in the United States live with CKD. Of that, 90% are typically unaware of their condition and many only learn of their diagnosis when they “crash” into dialysis in a hospital ER. At this point, the disease has progressed to its most serious stage, ESRD, which requires the patient to receive dialysis or a kidney transplant to survive. An estimated 746,557 people are living with ESRD, and each year approximately 20,000 people are newly diagnosed. Caring for patients with CKD/ESRD is complex and costly. In 2017, Medicare alone spent $120 billion to care for people living with CKD and ESRD. Early detection, lifestyle changes, and treatment are the most effective means of managing the disease, delaying its progression, and enabling the patient to live a better life longer. “Kidney disease is a widespread health care problem that is growing rapidly. Recent regulatory changes are driving much needed innovation and important advances in how we care for those living with this progressive, chronic condition, as well as prevent those most at risk from developing it,” said Eric Reimer, Chief Executive Officer at Healthmap Solutions. “At Healthmap Solutions, we share Health New England’s commitment to compassionate and life-improving kidney care. Our Kidney Health Management program delivers on this promise through whole patient care, supportive and collaborative partnerships with providers, and clinically proven treatment recommendations that improve care, member experiences and lower costs.” Healthmap’s KHM program incorporates big data, artificial intelligence, machine learning, and predictive analytics to identify people living with CKD. Combined with clinical expertise, the program provides health care providers with actionable, data-driven, clinically proven insights and patient-centered care recommendations. The company's multidisciplinary Care Navigation team collaborates with health care providers and specialists to coordinate patient care and recommend medication modifications as warranted. Additionally, the Care Navigation team connects with patients to provide the support and information needed to help manage their health care. The program results are measured and reported against outcome metrics, and modifications so care or treatment plans can be made to optimize quality health care outcomes and manage costs. "Healthmap is driven by our passion and commitment to manage the important role our health plan clients ask us to play in improving the lives of their members with complex chronic conditions such as kidney disease," said Thomas P. Gaffney Jr., Healthmap Solutions’ Chief Growth Officer. "The KHM program combines our population health management expertise with the clinical and technological acumen to provide a solution focused on cost-effective, clinical quality for members. The entire Healthmap team is looking forward to supporting Health New England, its providers and members requiring kidney health management services." About Health New England Based in Springfield, Massachusetts, Health New England is a not-for-profit health plan serving members in Massachusetts and Connecticut. A wholly-owned subsidiary of Baystate Health, Health New England offers a range of health care plans in the commercial, Medicaid and Medicare markets. For more information, visit healthnewengland.org . About Healthmap Solutions Healthmap Solutions is a leading Kidney Health Management (KHM) company. The company serves health plans, accountable care organizations (ACOs), and provider groups seeking value-based solutions that improve the clinical care and financial performance of high-risk, high-cost kidney patient populations. Healthmap has a rich history forged in data and analytics, having begun as a health care data clearinghouse, and going on to add robust health analytics expertise. Today, Healthmap uses that experience to power a complex KHM program with its clinical experts. For more information, visit healthmapsolutions.com . Contact:

New England Partners Investments

58 Investments

New England Partners has made 58 investments. Their latest investment was in Eyegate Pharmaceuticals as part of their Series D - II on January 1, 2011.

CBI Logo

New England Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/10/2011

Series D - II

Eyegate Pharmaceuticals

$5.9M

No

1/17/2008

Series A

Cequent Pharmaceuticals

$13.5M

Yes

6/8/2007

Series D

OmniSonics Medical Technologies

$20M

No

5/11/2007

Seed VC

Subscribe to see more

$99M

Subscribe to see more

0

1/16/2007

Series B

Subscribe to see more

$99M

Subscribe to see more

0

Date

1/10/2011

1/17/2008

6/8/2007

5/11/2007

1/16/2007

Round

Series D - II

Series A

Series D

Seed VC

Series B

Company

Eyegate Pharmaceuticals

Cequent Pharmaceuticals

OmniSonics Medical Technologies

Subscribe to see more

Subscribe to see more

Amount

$5.9M

$13.5M

$20M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

0

0

New England Partners Portfolio Exits

17 Portfolio Exits

New England Partners has 17 portfolio exits. Their latest portfolio exit was Magellan Biosciences on March 25, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/25/2016

Acquired

$99M

1

2/20/2015

IPO

$99M

Public

1

1/18/2013

Acquired

$99M

1

9/6/2012

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

10/27/2011

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/25/2016

2/20/2015

1/18/2013

9/6/2012

10/27/2011

Exit

Acquired

IPO

Acquired

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

New England Partners Acquisitions

3 Acquisitions

New England Partners acquired 3 companies. Their latest acquisition was TOG Manufacturing Company on December 08, 2006.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/8/2006

$99M

Acq - Fin

12/5/2003

Debt

Subscribe to see more

$99M

$99M

Subscribe to see more

0

5/19/1998

Subscribe to see more

$99M

Subscribe to see more

0

Date

12/8/2006

12/5/2003

5/19/1998

Investment Stage

Debt

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Total Funding

$99M

Note

Acq - Fin

Subscribe to see more

Subscribe to see more

Sources

0

0

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.